Category: 1260667-65-9

So far, in addition to halogen atoms, other non-metallic atoms can become part of the aromatic heterocycle, and the target ring system is still aromatic.Barlaam, Bernard; Casella, Robert; Cidado, Justin; Cook, Calum; De Savi, Chris; Dishington, Allan; Donald, Craig S.; Drew, Lisa; Ferguson, Andrew D.; Ferguson, Douglas; Glossop, Steve; Grebe, Tyler; Gu, Chungang; Hande, Sudhir; Hawkins, Janet; Hird, Alexander W.; Holmes, Jane; Horstick, James; Jiang, Yun; Lamb, Michelle L.; McGuire, Thomas M.; Moore, Jane E.; O’Connell, Nichole; Pike, Andy; Pike, Kurt G.; Proia, Theresa; Roberts, Bryan; San Martin, Maryann; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren; Sumner, Neil; Thakur, Kumar; Vasbinder, Melissa M.; Varnes, Jeffrey G.; Wang, Jianyan; Wang, Lei; Wu, Dedong; Wu, Liangwei; Yang, Bin; Yao, Tieguang researched the compound: 5-Chloro-4-iodopyridin-2-amine( cas:1260667-65-9 ).Computed Properties of C5H4ClIN2.They published the article 《Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies》 about this compound( cas:1260667-65-9 ) in Journal of Medicinal Chemistry. Keywords: amidopyridine derivative AZD4573 preparation CDK9 inhibitor hematol malignancy. We’ll tell you more about this compound (cas:1260667-65-9).

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

When you point to this article, it is believed that you are also very interested in this compound(1260667-65-9)Computed Properties of C5H4ClIN2 and due to space limitations, I can only present the most important information.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies, published in 2020-12-24, which mentions a compound: 1260667-65-9, mainly applied to amidopyridine derivative AZD4573 preparation CDK9 inhibitor hematol malignancy, Quality Control of 5-Chloro-4-iodopyridin-2-amine.

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

Here is just a brief introduction to this compound(1260667-65-9)Quality Control of 5-Chloro-4-iodopyridin-2-amine, more information about the compound(5-Chloro-4-iodopyridin-2-amine) is in the article, you can click the link below.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

HPLC of Formula: 1260667-65-9. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations. Author is Karlsson, Staffan; Benson, Helen; Cook, Calum; Currie, Gordon; Dubiez, Jerome; Emtenaes, Hans; Hawkins, Janet; Meadows, Rebecca; Smith, Peter D.; Varnes, Jeffrey.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

There is still a lot of research devoted to this compound(SMILES：NC1=NC=C(Cl)C(I)=C1)HPLC of Formula: 1260667-65-9, and with the development of science, more effects of this compound(1260667-65-9) can be discovered.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations.COA of Formula: C5H4ClIN2.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

From this literature《From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations》,we know some information about this compound(1260667-65-9)COA of Formula: C5H4ClIN2, but this is not all information, there are many literatures related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations.Electric Literature of C5H4ClIN2.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

There is still a lot of research devoted to this compound(SMILES：NC1=NC=C(Cl)C(I)=C1)Electric Literature of C5H4ClIN2, and with the development of science, more effects of this compound(1260667-65-9) can be discovered.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Quality Control of 5-Chloro-4-iodopyridin-2-amine. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations. Author is Karlsson, Staffan; Benson, Helen; Cook, Calum; Currie, Gordon; Dubiez, Jerome; Emtenaes, Hans; Hawkins, Janet; Meadows, Rebecca; Smith, Peter D.; Varnes, Jeffrey.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

If you want to learn more about this compound(5-Chloro-4-iodopyridin-2-amine)Quality Control of 5-Chloro-4-iodopyridin-2-amine, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Recommanded Product: 1260667-65-9. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. Author is Barlaam, Bernard; Casella, Robert; Cidado, Justin; Cook, Calum; De Savi, Chris; Dishington, Allan; Donald, Craig S.; Drew, Lisa; Ferguson, Andrew D.; Ferguson, Douglas; Glossop, Steve; Grebe, Tyler; Gu, Chungang; Hande, Sudhir; Hawkins, Janet; Hird, Alexander W.; Holmes, Jane; Horstick, James; Jiang, Yun; Lamb, Michelle L.; McGuire, Thomas M.; Moore, Jane E.; O’Connell, Nichole; Pike, Andy; Pike, Kurt G.; Proia, Theresa; Roberts, Bryan; San Martin, Maryann; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren; Sumner, Neil; Thakur, Kumar; Vasbinder, Melissa M.; Varnes, Jeffrey G.; Wang, Jianyan; Wang, Lei; Wu, Dedong; Wu, Liangwei; Yang, Bin; Yao, Tieguang.

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

If you want to learn more about this compound(5-Chloro-4-iodopyridin-2-amine)Recommanded Product: 1260667-65-9, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called From Milligram to Kilogram Manufacture of AZD4573: Making It Possible by Application of Enzyme-, Iridium-, and Palladium-Catalyzed Key Transformations, published in , which mentions a compound: 1260667-65-9, Name is 5-Chloro-4-iodopyridin-2-amine, Molecular C5H4ClIN2, Related Products of 1260667-65-9.

With the first generation medicinal chem. synthesis as a starting point, herein process development of AZD4573, an oncol. drug candidate was described. In addition to improved yields and removal of chromatog. steps, other factors such as availability of starting materials as well as safety of the chem. involved were addressed. With several steps involving volatile, reactive, and non-UV active materials, reaction optimization was facilitated by implementing off-line 1H NMR anal. of crude mixtures Key transformations targeted for process development included a Wolff-Kishner reduction, an iridium-catalyzed borylation, and enzymic resolution of a racemic amino-ester.

In some applications, this compound(1260667-65-9)Related Products of 1260667-65-9 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Name: 5-Chloro-4-iodopyridin-2-amine. The reaction of aromatic heterocyclic molecules with protons is called protonation. Aromatic heterocycles are more basic than benzene due to the participation of heteroatoms. Compound: 5-Chloro-4-iodopyridin-2-amine, is researched, Molecular C5H4ClIN2, CAS is 1260667-65-9, about Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. Author is Barlaam, Bernard; Casella, Robert; Cidado, Justin; Cook, Calum; De Savi, Chris; Dishington, Allan; Donald, Craig S.; Drew, Lisa; Ferguson, Andrew D.; Ferguson, Douglas; Glossop, Steve; Grebe, Tyler; Gu, Chungang; Hande, Sudhir; Hawkins, Janet; Hird, Alexander W.; Holmes, Jane; Horstick, James; Jiang, Yun; Lamb, Michelle L.; McGuire, Thomas M.; Moore, Jane E.; O’Connell, Nichole; Pike, Andy; Pike, Kurt G.; Proia, Theresa; Roberts, Bryan; San Martin, Maryann; Sarkar, Ujjal; Shao, Wenlin; Stead, Darren; Sumner, Neil; Thakur, Kumar; Vasbinder, Melissa M.; Varnes, Jeffrey G.; Wang, Jianyan; Wang, Lei; Wu, Dedong; Wu, Liangwei; Yang, Bin; Yao, Tieguang.

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after i.v. administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated ED. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematol. cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematol. tumors. Compound 24 is currently in clin. trials for the treatment of hematol. malignancies.

From this literature《Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies》,we know some information about this compound(1260667-65-9)Name: 5-Chloro-4-iodopyridin-2-amine, but this is not all information, there are many literatures related to this compound(1260667-65-9).

Reference:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia